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Anthracycline antibiotics (e.g. doxorubicin and daunorubicin) are among the most effective and widely used anticancer drugs. Unfortunately,
their clinical use is limited by the dose-dependent cardiotoxicity. Flavonoids represent a potentially attractive class of compounds to mitigate the
anthracycline cardiotoxicity due to their iron-chelating, antioxidant and carbonyl reductase-inhibitory effects. The relative contribution of various
characteristics of the flavonoids to their cardioprotective activity is, however, not known. A series of ten flavonoids including quercetin, quercitrin,
7-monohydroxyethylrutoside (monoHER) and seven original synthetic compounds were employed to examine the relationships between their
inhibitory effects on carbonyl reduction, iron-chelation and antioxidant properties with respect to their protective potential against doxorubicin-
induced cardiotoxicity. Cardioprotection was investigated in the neonatal rat ventricular cardiomyocytes whereas the H9c2 cardiomyoblast cells
were used for cytotoxicity testing. Iron chelation was examined via the calcein assay and antioxidant effects and site-specific scavenging were
quantified by means of inhibition of lipid peroxidation and hydroxyl radical scavenging activity, respectively. Inhibition of carbonyl reductases was
assessed in cytosol from human liver. None of the flavonoids tested had better cardioprotective action than the reference cardioprotector, monoHER.
However, a newly synthesized quaternary ammonium analog with comparable cardioprotective effects has been identified. No direct correlation
between the iron-chelating and/or antioxidant effect and cardioprotective potential has been found. A major role of carbonyl reductase inhibition
seems unlikely, as the best two cardioprotectors of the series are only weak reductase inhibitors.
© 2007 Elsevier B.V. All rights reserved.Keywords: Anthracyclines; Cardioprotection; Iron chelator; Hydroxyl radical scavenging; Lipid peroxidation; Doxorubicinol1. Introduction
Anthracyclines, of which doxorubicin is the leading com-
pound, are among the most potent anticancer drugs, however,
their use is limited by the risk of severe cardiotoxicity [1].
Various plausible hypotheses have been proposed to explain
doxorubicin-induced cardiotoxicity (for reviews see [2,3]). It is
generally thought to be caused by free radicals generated during
redox cycling of doxorubicin and/or cardiotoxic action of⁎ Corresponding author. Institute of Organic Chemistry and Biochemistry
Academy of Sciences of the Czech Republic Flemingovo nam. 2 166 10 Prague
6 Czech Republic. Tel.: +420 220 183 114; fax: +420 220 183 560.
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doi:10.1016/j.bbadis.2007.05.002doxorubicinol, a C13-dihydrometabolite of doxorubicin. There-
fore, pharmacological agents which would be able to suppress
the formation of both doxorubicinol and reactive oxygen spe-
cies merit intense investigations.
Flavonoids are a group of benzo-γ-pyron derivatives,
naturally found in the diet, which exhibit numerous pharmaco-
logical properties that are beneficial for human health [4]. With
respect to doxorubicin cardiotoxicity, their antioxidant activity,
iron-chelating properties and inhibitory effects on carbonyl
reductases are of interest. Evidence has been given that the
flavonoids indeed have a strong potential to relieve doxo-
rubicin-induced cardiac side-effects [5,6,7]. However, it is not
fully elucidated yet, which of their pharmacological properties
are essential for their cardioprotective action.
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dependent reduction to its C13-dihydrometabolite (doxorubici-
nol), which has been shown to be more cardiotoxic than the
parent drug [8,9]. Several ubiquitous cytosolic enzymes, such as
carbonyl reductases (CR) and aldo-keto reductases participate
in the formation of C13-dihydroanthracyclines. CRs, in parti-
cular, seem to play an important role in anthracycline-induced
cardiotoxicity [10,11,12]. Flavonoids like quercetin or rutin are
known inhibitors of CR [13] and might therefore act as phar-
macological inhibitors of doxorubicinol formation.
Doxorubicin generates reactive oxygen species (ROS),
which have been suggested to play an important role in the
development of cardiotoxicity [3]. Free radical scavengers
have therefore been proposed to protect cardiac tissue from
doxorubicin-induced oxidative stress and thus to relieve its
cardiotoxicity. Most of the flavonoids possess excellent
antioxidant properties and the relationships between their
structure and antioxidant activity have been well described
[14].
Whereas common antioxidants inactivate ROS only after
they have been formed, iron chelators are able to prevent their
formation. Iron can redox-cycle between its two redox states –
Fe2+ and Fe3+ – and acts as a catalyst of hydroxyl radical
formation (Fenton and Haber–Weiss reactions). Iron chelation
is considered to be an important tool to decrease anthracycline
cardiotoxicity as documented by the beneficial effect of
dexrazoxane [15] as well as other chelators of iron [16,17]. InFig. 1. Chemical structures of the flavonoids under investigation. F4=7-mflavonoids, the antioxidant and iron chelating properties are
closely related and their activity may include two steps — iron
is first chelated by the flavonoid and the ROS which are formed
in its vicinity are subsequently scavenged by the flavonoid. In
this way, the radicals are quenched at the same place where they
are formed. This concept has been called site-specific scaven-
ging [18].
For this comparative study, we have used a series of ten
differently substituted flavonoids (Fig. 1), of which seven were
newly synthesized [19] and three were commercially available.
Some of these compounds have been well characterized by now,
for example 7-monohydroxyethylrutoside has already proved to
be highly efficient against the cardiotoxicity of doxorubicin
[5,20] and has recently entered phase II clinical trials. Quercetin
and its O-glucoside, quercitrin, also represent extensively
studied flavonoids being among the most common dietary
polyphenols and the components of various food nutrients. The
flavonoids were synthesized with the objective to discern the
structural requirements that are essential for a good cardiopro-
tective activity of the flavonoids.
The aim of this work was to describe and compare the
inhibitory effects of the flavonoids on doxorubicin carbonyl
reduction, their iron-chelating and antioxidant properties as well
as their general toxicity: all in relation to their molecular
structure. Most importantly, we aimed to assess, which of those
features are especially important for the cardioprotective effect
of the flavonoids.onohydroxyethylrutoside (monoHER), F5=quercetin, F6=quercitrin.
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2.1. Chemicals
7-monohydroxyethylrutoside (monoHER) was kindly provided by Novartis
Consumer Health, Nyon, Switzerland, quercetin and quercitrin were obtained
from Sigma-Aldrich, Prague, Czech Republic and the substituted flavonoids
were synthesized as described elsewhere [19]. Formulated doxorubicin
(doxorubicin hydrochloride 2 mg mL−1) was obtained from TEVA (Pharma-
chemie B.V., Haarlem, The Netherlands). Doxorubicinol was a kind gift from
Assoc. Prof. Bruce G. Charles (University of Queensland, Brisbane, Australia).
SIH was obtained from Prof. P. Ponka (Mc Gill University, Montréal, Canada).
All other chemicals were of the highest grade available.
2.2. Cell culture
Primary cardiomyocyte cultures were prepared from 2-day-old neonatal
Wistar rats (BioTest, Konárovice, Czech Republic) according to Vlasblom et al.
[21]. All the procedures have been conducted in accordance with the Declaration
of Helsinki and approved and supervised by the Ethical Committee of the
Faculty of Pharmacy in Hradec Králové, Charles University in Prague. The
animals were anaesthetized with CO2 and decapitated. The chests were opened
and the hearts were collected in an ice-cold ADS buffer. The ventricles were
thoroughly minced and serially digested with a mixture of collagenase II
(0.25 mg mL−1; Gibco) and pancreatin (0.4 mg mL−1; Sigma) solution at 37 °C.
The obtained cell suspension was placed on a 15-cm covered Petri dish and left
for 2 h at 37 °C in order to separate the myocytes (floating in the medium) from
the fibroblasts (attached to the dish). The myocyte suspension was collected and
viable cells counted using trypan blue exclusion. Cells were plated on the
gelatine-coated 12-well plates at a density of 800,000 cells per well in the
DMEM/F12 (1:1) growth medium containing 10% horse serum, 5% FCS, 1%
Pen/Strep and 4% sodium pyruvate. After 40 h, the medium was renewed and
the serum concentration was lowered to 5% (FCS). The medium was changed
once more after another 24 h and the experiments were performed at the 4th day
after the isolation using both serum and pyruvate-free medium.
For ethical reasons, primary cardiomyocytes were only used in a few major
experiments (cardioprotection assessment) whereas they were replaced by rat
cardiomyoblast cell line (H9c2) for routine cytotoxicity screening. The H9c2
cell line (ATCC, Manassas, VA, USA) was maintained in DMEM sup-
plemented with 10% heat-inactivated FBS (Cambrex Inc., Walkersville, USA),
100 U mL−1 of penicillin and 100 μg mL−1 of streptomycin (PAA, Pasching,
Austria) and grown under humidified atmosphere containing 5% CO2 at 37 °C.
Cell passages between 25 and 40 were used for cytotoxicity experiments.
2.3. LDH leakage assay
The cardiomyocytes were preincubated with the test compounds dissolved
in DMSO (0.2% final concentration) for 30 min. Thereafter, 1 μM of doxo-
rubicin was added and the medium was sampled after 24, 48 and 72 h. Activity
of released LDH was assayed in Tris–HCl buffer pH 8.9 containing 35 mM of
lactic acid (Sigma Aldrich, Prague, Czech Republic) and 5 mM of NAD+ (MP
Biomedicals, Irvine, CA, USA). The rate of NAD+ reduction was monitored
spectrophotometrically at 340 nm (Helios β, Unicam). LDH activity was
calculated using molar absorption coefficient ε=6.22×103 M−1 cm−1.
2.4. Neutral red uptake (NRU) cytotoxicity assay
In order to assess the cytotoxicity of the tested flavonoids to the target cells,
the viability of the H9c2 rat cardiomyoblast cell line was assayed by the NRU
method. The cells were plated in flat-bottom microtiter plates at a cell density of
10,000 cells per well. After a 24-h preincubation period, cells were incubated
with the flavonoids for another 48 or 96 h and tested for viability. Briefly,
40 μg mL−1 of neutral red (Sigma-Aldrich, Prague, Czech Republic) was added
to each well. After incubation for 3 h at 37 ° C, the supernatant was discarded,
cells were fixated with 1% CaCl2 in 0.5% formaldehyde for 15 min, washed
twice with PBS and solubilized with 1% acetic acid in 50% ethanol. The optical
density of soluble neutral red was measured at 540 nm using a BioRad micro-plate reader. Cytotoxicity was expressed as the IC50 values, which were deter-
mined using GraphPad Prism version 4.00 for Windows (GraphPad Software,
San Diego CA, USA).
2.5. Preparation of cytosolic fractions
The human liver samples from five male (18, 24, 52, 56 and 60 years old)
and one female (55 year old) donors were obtained from the Cadaver Donor
Program of the Transplantation Centre of the Faculty of Medicine, Charles
University, Hradec Králové. Cut part of liver (lobus hepatis sinister) in ice-
cooled Eurocollins solution was transported from the hospital to the laboratory
(less than 30 min) and stored in the freezer (−80 °C). Frozen liver samples were
thawed at room temperature (up to 15 min) and homogenized at a 1:6 (w/v) ratio
in 0.1 M sodium phosphate buffer, pH 7.4, using a Potter–Elvehjem homo-
geniser and sonication with Sonopuls (Bandeline, Germany). The cytosolic
fractions were isolated by fractional ultracentrifugation of the resulting homo-
genate (the first 105,000×g supernatant was considered the cytosolic fraction).
Protein concentration was assayed using the bicinchoninic acid method [22] and
the cytosolic fractions were stored at −80 °C.
2.6. Doxorubicin carbonyl reduction assay
Cytosolic carbonyl reductases (CR) catalyze the formation of the most cha-
racteristic metabolite of doxorubicin — C13-dihydrodoxorubicin (doxorubici-
nol). We have therefore followed the rate of doxorubicinol formation in human
liver cytosol to describe the potency of various flavonoids to inhibit CR. Unless
otherwise indicated, C13 carbonyl reduction of doxorubicin was assayed by
incubating 1 mg mL−1 of cytosolic fraction with 1 mM of doxorubicin in 50 mM
sodium phosphate buffer (total volume of 150 μL) and the reaction was started
with 0.5 mM NADPH (Serva, Heidelberg, Germany). To assess an inhibitory
action of the flavonoids on carbonyl reduction, the test compounds were prein-
cubated with the cytosolic fractions for 5 min prior to the addition of doxoru-
bicin and NADPH. Control experiments were performed without biological
material. The reactions were carried out at 37 °C and stopped after 60 min by
adding an equal volume (150 μL) of 0.2 M Na2HPO4 pH 8.4 while cooling the
reaction mixture on ice. The anthracyclines were extracted with 1.2 mL of a 9:1
(v/v) chloroform/1-heptanol mixture. After 15 min of vigorous shaking, samples
were centrifuged at 5000×g for 10 min to separate the layers. The lower organic
phase was carefully removed to another microtube and re-extracted with 150 μL
of 0.1 M o-phosphoric acid. After 1 min of vigorous shaking the upper aqueous
layer was removed to a vial and subjected to the HPLC analysis [23]. The
activity of the flavonoids was expressed as IC50 being the concentration of the
flavonoid causing 50% reduction in doxorubicinol formation.
2.7. Determination of doxorubicinol
Following the extraction, doxorubicin and doxorubicinol were separated and
detected using the Agilent 1100 series HPLC system (Agilent Technologies,
Inc.). Reverse-phase chromatography was performed with a Supelco Discovery
C18 analytical column (15 cm×4 mm, 5 μm) protected with a guard column.
The analytes (25 μL) were isocratically eluted with a freshly prepared mobile
phase consisting of 50 mM sodium phosphate buffer pH 4.0 and acetonitrile in a
75:25 (v/v) ratio. The flow rate was 1.5 mL min−1. Under these conditions the
substances eluted at 2.2 min (doxorubicinol) and 3.8 min (doxorubicin) as
monitored spectrofluorimetrically with excitation wavelength of 480 nm and
emission wavelength of 560 nm. Quantification of doxorubicinol was performed
with the aid of a calibration curve constructed by using known concentrations of
authentic doxorubicinol. All data are mean from at least 3 separate experiments
performed in duplicates. Standard deviations were less than 10%.
2.8. Calcein assay for iron chelation
Chelator efficiency was determined using a calcein assay according to
Cabantchik et al. [24] Fluorescence of free calcein (Molecular Probes, Eugene,
OR, USA) was measured with a LS50B Perkin Elmer spectrofluorimeter equip-
ped with a magnetic stirrer. The measurements (λex=486 nm, λem=517 nm)
were done at room temperature and recorded as a function of time. Due to high
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displacement of iron from its complex with calcein and the concentration of the
chelators therefore had to be adjusted accordingly to a lower level (5 μM)
compared to the concentrations used in other assays described in this manuscript.
Briefly, calcein (20 nM in HEPES-buffered saline, pH 7.2) was incubated for 1 h
with ferrous ammonium sulphate (200 nM), after which at least 95% of
fluorescence was quenched. The calcein–iron complexes were then exposed to
test compounds (5 μM) for 500 s. After that, in order to obtain maximal
dequenching, 5 μM of SIH was added and the reaction was followed for
additional 500 s. Background fluorescence did not exceed 3% throughout the
experiment. Data were analyzed using FLWinLab Software (Perkin Elmer) and
normalized to the maximal fluorescence attained by the treatment with SIH, a
reference iron chelator, which was previously shown to efficiently shield the
cellular labile iron pool and completely block the Fenton reaction-mediated
oxidative damage [25].
2.9. Kinetics of displacement of iron from doxorubicin–Fe3+
complexes
The spectrophotometric assay was performed according to Hasinoff et al.
[26]. Briefly, the doxorubicin–Fe3+ (3:1) complex was prepared by adding
FeCl3 in 15 mM HCl to doxorubicin solution. The resulting complex, which
revealed a typical absorption band at λ=600 nm (9-fold increase as compared to
uncomplexed doxorubicin) was added to the reaction buffer (50 mM Tris /
150 mM KCl, pH=7.4, room temperature) in the glass cuvette to yield final
concentration of 45 μM doxorubicin/15 μM Fe3+. After the 3-min equilibration
period, tested flavonoids or reference chelators (SIH, EDTA) were added in an
amount to obtain 100 μM final concentration. The absorbance at λ=600 nm was
then followed for another 8 min.
2.10. Hydroxyl radical scavenging assay
Hydroxyl radical scavenging capacity was assayed by the 2-deoxyribose
(DR) method according to Halliwell et al. [27]. It is based on the competition
between the flavonoids and 2-deoxyribose for hydroxyl radicals. Upon the
reaction with hydroxyl radicals, 2-deoxyribose is degraded into a mixture of
thiobarbituric acid (TBA)-reactive products, which can be quantified spectro-
photometrically. The incubation mixture contained: H2O2 (2.8 mM), EDTA
(when indicated, 100 μM), 2-deoxyribose (2.8 mM), ascorbate (100 μM) and
ferric chloride (20 μM). The concentrations of the flavonoids ranged from 100 to
500 μM. The reaction mixtures were incubated at 37 °C for 1 h. The reaction
was stopped by the addition of TBA reagent, freshly prepared by mixing 9 parts
of reagent A (2.8 mMTBA, 0.125MHCl, 16.8% (w/v) trichloracetic acid) and 1
part of reagent B (1.5 mg mL−1 solution of butylated hydroxytoluene inTable 1
Protection of the flavonoids against doxorubicin-induced toxicity in rat neonatal ven
24 h 48 h
LDH activity
(mUd L−1 min−1)
Protection vs.
DOX (%)
LDH activity
(mUd L−1d m
Control 18±4 26±8
DOX 72±8 130±7
F1±DOX 92±2 None 138±4
F2±DOX 53±10 37 101±4∗
F3±DOX 54±10 35 105±9
F4±DOX 39±10∗∗ 58 68±7∗∗
F5±DOX 23±3∗∗ 91 96±15∗
F6±DOX 57±18 24 94±10∗
F7±DOX 47±6∗ 46 86±13∗∗
F8±DOX 69±12 8 119±8
F9±DOX 57±9 29 108±11
F10±DOX 36±10∗∗ 69 114±16
Data express LDH activity in the extracellular media and the percentual ability
(100%=complete protection).
Values represent means±SD from three to four separate experiments. ∗pb0.05; ∗∗pethanol). Subsequently, the reaction mixture was heated for 15 min at 99 °C.
After centrifugation (3000×g, 7 min), the absorbance (532 nm) was measured.
The second-order rate constant of the scavenger (ks) with the hydroxyl radical
can be calculated using a rate constant of 3.1×109 M−1 s−1 for deoxyribose
(kDR). The absorbance at 532 nm (A) depends on the concentration of the
scavenger ([S]) and the absorbance found without scavenger (A0). The ks value
of the scavenger is obtained from the slope of the linear plot of the reciprocal
value of Aversus [S] and calculated as follows: ks=slope×kDR×[DR]×A0 [27].
2.11. Lipid peroxidation assay
LPO was assayed as described elsewhere [6]. Briefly, heat-inactivated
microsomes from rat liver were incubated with ascorbate (200 μM) and ferrous
sulphate (10 μM) at 37 °C for up to 60 min. At t=0, 5, 10, 15, 30, 45 and 60 min,
an aliquot of 0.3 ml was mixed with 2 mL of TBA–trichloroacetic acid–HCl–
butylated hydroxytoluene solution to stop the reaction. The reagent was
prepared as described in the hydroxyl-scavenging assay. After heating (15 min,
80 °C) and centrifugation (15 min), the absorbance at 535 vs. 600 nm was
determined. The IC50 was determined by measuring the percentage of LPO
inhibition at several concentrations and calculating the concentration at which
50% inhibition was obtained.
2.12. Statistical analysis
Unless otherwise indicated, the data are given as the mean of at least three
separate experiments±SD. One-way ANOVA with Tukey's post hoc test was
performed to test for differences between groups using GraphPad Prism version
4.00 for Windows (GraphPad Software, San Diego, CA). Pearson product
moment correlation analyses were performed using SigmaStat for Windows
version 3.0.1. (SPSS Inc. Chicago, IL).3. Results
3.1. Assessment of cardiac protection
Using a model of neonatal rat ventricular cardiomyocytes we
investigated the protective activity of the flavonoids against
doxorubicin toxicity. Cellular damage was quantified via
measurement of the time-dependent LDH release from the
cells (Table 1). We found that after 24 h incubation of the cells
with 1 μM of doxorubicin and 100 μM of the flavonoids, fourtricular cardiomyocytes (NVCM)
72 h
in−1)
Protection vs.
DOX (%)
LDH activity
(mUd L−1d min−1)
Protection vs.
DOX (%)
43±1
156±3
None 173±10 None
29 146±4 8
25 142±5 12
55 90±10∗∗ 58
34 154±10 1
30 135±0 18
42 109±3∗∗ 41
12 151±1 5
22 140±4 14
17 150±1 5
of the flavonoids (100 μM) to reverse DOX (1 μM)-induced LDH leakage
b0.001 (one-way ANOVAwith Tukey's post-hoc test).
Fig. 2. Optimization of the reaction conditions for the carbonyl reduction inhi-
bition studies. (A) Michaelis–Menten plot of doxorubicinol formation as a
function of the doxorubicin concentration, (B) the effect of NADPH concen-
tration using a fixed (1 mM) concentration of doxorubicin and (C) doxorubicinol
formation in time (DOX 1 mM, NADPH 0.5 mM). All values are given as
means±SD from three separate experiments.
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four compounds (F2, F3, F6, F9) reached 20–30% protection
whereas the two remaining flavonoids (F1, F8) were not
protective. After 48 and 72 h incubation, only F4 and F7 main-
tained their high protective effect (N40%). An initial promising
effect of F5 and F10 decreased dramatically, most probably
due to their high intrinsic toxicity (see the cytotoxicity section,
Table 2). Although the protective action of quercetin (F5) was
still significant at 48 h, it disappeared completely after 72 h. On
the other hand, the effect of moderate protectors—F2, F3, F6
and F9 was more stable during the incubation period, albeit
weaker. In summary, none of the flavonoids was more effective
than F4 (monoHER), F7 being the only one which had a com-
parable effect throughout the whole experiment (up to 72 h).
The flavonoids F1 and F8, which lacked any protective pro-
perties from the beginning, and also F5 (quercetin) and F10,
which showed a clear short-term protection that however quick-
ly disappeared, are clearly the least interesting agents for further
investigation as potential cardioprotectors.
3.2. Carbonyl reductase inhibition and cytotoxicity evaluation
First of all, we have optimized the method for doxorubicinol
determination in our cytosolic samples using various substrate
(doxorubicin) and coenzyme (NADPH) concentrations as well
as incubation time points (Fig. 2). As a result we standardly
used 1 mM of doxorubicin, 0.5 mM of NADPH and the incu-
bations were stopped after 60 min, during which the reaction
rate was linear. We have found that all of the tested flavonoids
were capable of inhibiting doxorubicinol formation, although
their potency strongly differed. The IC50 values for the inhi-
bition of doxorubicinol formation are shown in Table 2. Quer-
cetin and quercitrin (F5, F6) were the most effective inhibitors
in the series of the present study. The only synthetic flavonoid
with comparable potency was F10, indicating that neither the
methylation of C3–OH nor the presence of C4–OH has
influence on the CR inhibitory effect. However, the substitution
of C3–OH with an aliphatic chain containing a quaternary am-
monium moiety decreased the inhibitory effect (F9 vs. F10).Table 2
Carbonyl reductase inhibition by the flavonoids in human liver cytosol and their
cytotoxicity in the rat cardiomyoblast cell line (H9c2)
CR inhibition Cytotoxicity to H9c2
IC50 (μM) IC50 48h (μM) IC50 96 h (μM)
F1 35±6 96±23 44±8
F2 50±7 N500 271±29
F3 71±13 N500 417±108
F4 84±27 340±123 463±182
F5 18±2 133±33 44±6
F6 12±4 N500 N500
F7 170±40 N500 N500
F8 67±13 341±144 146±36
F9 46±4 N500 466±33
F10 20±2 243±38 37±10
IC50= the concentration of a flavonoid which caused 50% decrease in doxo-
rubicinol formation or 50% decrease in cell viability, respectively.
Values represent means±SD from three separate experiments.The viability of the H9c2 cells is shown as a function of
either concentration of the flavonoids (Table 2) or time (Fig. 3).
It is clear that the toxicity decreases with the degree of subs-
titution of the hydroxyl groups, because the simplest structures,
e.g. F1, F5 or F10, are the most toxic ones. Glycosylation (F2,Fig. 3. Time-dependent plot of the cytotoxic effects of the flavonoids (100 μM)
in H9c2 cells. Values represent means from three separate experiments. Error
bars not indicated for sake of clarity.
Fig. 4. Kinetics of the displacement of Fe3+ from the Fe3+–doxorubicin complex
by reaction with the flavonoids and reference chelators (SIH, EDTA). The
measurements were made spectrophotometrically at 600 nm in TRIS–KCl
buffer pH 7.4 at 25 °C. For sake of clarity, time plots of three representative
flavonoids out of ten are shown: F5 represents the flavonoid with high chelating
capacity whereas F1 and F4 represent those with low chelating capacity
according to the calcein assay. All other flavonoids investigated displayed a
similar pattern of unreactivity with Fe3+–doxorubicin complexes.
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moieties (F7, F8, and F9) lead to a decrease in the toxicity.
3.3. Iron chelation and antioxidant effects
All the tested flavonoids were found to chelate iron as
demonstrated by their ability to displace iron from the iron–
calcein complex. Nevertheless, their efficacy was considerably
lower than the reference iron chelator SIH, which is able to
displace iron from the iron–calcein complex both quickly and
completely. The flavonoids did not vary strongly in their ability
to chelate iron and after 500 s of incubation, the activity of all
the compounds reached from 12 to 39% of the maximal effect
(Table 3, first column). The most efficient chelators of iron were
F5 and F6. This can be explained by the presence of an
additional iron-chelating moiety in their molecular structure
(between 5-OH and 4-oxo groups) whereas other structures
(with an exception of F4) appear to chelate iron only when the
o-catechol group in ring B is present.
Although all the flavonoids under investigation removed
iron from its complexes with calcein to some extent, none of
them was capable of displacing iron from doxorubicin–iron
complex in a fashion that is typical for strong chelators like SIH
or EDTA (Fig. 4). This indicates higher affinity of Fe3+ to
doxorubicin than to flavonoids.
The deoxyribose assay for hydroxyl radical scavenging was
performed in the absence or presence of the strong metal che-
lator, EDTA and the second-order rate constants of the flavo-Table 3
Site-specific scavenging of hydroxyl radicals expressed as second-order rate
constants of the flavonoids with hydroxyl radicals (ks), relative iron (III)
chelation expressed as percentage of the effect of the reference chelator SIH and
prevention of lipid peroxidation by the flavonoids
Fe3+ chelation a
(% of SIH)
ks
b [M−1 s−1]×109 Without EDTA:
with EDTA ratio
LPOc
IC50
(μM)
Without
EDTA
With
EDTA
F1 15±2 57±18 10±2 6 22±6
F2 13.7±0.6 53±12 9±2 6 2.8±0.9
F3 14.8±0.5 69±5 28 ± 2 2 16±5
F4 11.7±0.2 106±15 8±2 13 13±4
F5 39.4±0.1 20±4 −1±0 15 5.1±0.1
F6 29.1±0.9 62±11 6±2 10 n.d.
F7 22.8±0.1 53±13 10±2 5 37±2
F8 18.3±0.4 52±8 19±2 3 1.4±0.3
F9 16.4±0.8 107±16 24±2 4 3.8±0.1
F10 18.5±0.3 48±11 11±1 4 1.6±0.7
IC50= the concentration of the flavonoid at which 50% inhibition of LPO was
obtained.
n.d. — not determined.
Values represent means±SD from at least three separate experiments.
a Measured as displacement of Fe3+ from its complexes with calcein after 500 s
of incubation (complete displacement by SIH).
b Hydroxyl radicals were generated in presence of H202 (2.8 mM),
Fe3+(20 μM), ascorbate (100 μM), EDTA (100 μM, where indicated) and
2-deoxyribose (2.8 mM), which was used as a detector molecule.
c Lipid peroxidation was induced with Fe2+ (10 μM) and ascorbate (200 μM)
in heat-inactivated microsomes in presence/absence of various concentrations
of the flavonoids.noids with hydroxyl radicals (ks) are presented in the second and
third column of Table 3. Our results show that the ks values of
all tested flavonoids increased when EDTA was not present.
This effect was particularly pronounced with F4, F5 and F6
(Table 3, fourth column) and seems to be the result of an
additional chelating site in those molecules, represented by 4-
oxo group combined with 5-OH.
Lipid peroxidation (LPO) inhibition assays confirm that
most of the compounds studied are excellent antioxidants with
F2, F5, F8, F9, F10 being particularly effective (Table 3, last
column). Interestingly, the ability of the flavonoids to inhibit
LPO does not seem to correlate with hydroxyl radical sca-
venging potency where F3, F8, F9 acted as the best scavengers.
On the contrary, F5 (quercetin) promoted hydroxyl radical
formation although it was very effective against LPO. The high
efficiency of F8 and F9 could be attributed to the quaternary
ammonium group; nevertheless, this would not explain the
relatively lower efficiency of F7 and high efficiency of F3 at the
same time.
4. Discussion
For many years, flavonoids attract the attention of research-
ers because they possess multiple pharmacological properties
[28]. Some of their characteristics, namely the antioxidant, iron-
chelating and carbonyl reductase-inhibitory effects, render them
particularly interesting to investigate them as new protective
compounds against doxorubicin cardiotoxicity. Evidence has
been given that the semi-synthetic flavonoid monoHER is
cardioprotective in animal models [5]. This compound was also
shown not to interfere with the anticancer effects of doxorubicin
[29]. Because monoHER has to be administered at a high dose
and because of its low oral bioavailability, a series of new
synthetic derivatives with potentially enhanced antioxidant pro-
perties and/or better intestinal absorption have been synthesized
[19] in order to identify a compound with increased cardio-
protective properties. To achieve this goal, various types of
substitutions have been tested. An attempt was also performed
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tion of the quaternary ammonium moiety in various positions of
the flavonoid structure [30].
Antioxidant properties were long considered to be the major
or even sole determinants for efficient protectors against doxo-
rubicin cardiotoxicity because reactive oxygen species and
oxidative stress are considered to be involved in the pathophy-
siology of its development [31,32,33]. However, it has been
shown that there are pronounced differences in the cardiopro-
tective effects also among the flavonoids with comparable anti-
oxidant properties [6].
Apart from their antioxidant effects, other factors are ob-
viously involved in the protective properties of the flavonoids.
We conducted this study in order to explore these other features
that are likely to be involved in their cardioprotection. Iron
chelation was chosen because of an apparent involvement of
iron in doxorubicin-induced cardiotoxicity [34] and the effects
on carbonyl reduction of doxorubicin were examined because
its inhibition will prevent formation of the cardiotoxic C13-
dihydrometabolites of the anthracyclines [11,35]. The antiox-
idant properties and general cytotoxicity of the compounds have
also been evaluated. We attempted to determine structure–
activity relationships and most importantly, the collected data
were related to their cardioprotective potential in order to define
the characteristics that are essential for their cardioprotective
potency. This knowledge is vital for designing new efficient and
safe cardioprotectors.
The cardioprotective effects of the selected flavonoids were
assessed in neonatal rat cardiomyocytes. These experiments
were designed with concentrations of doxorubicin (1 μM),
which corresponded with plasma concentration in human pa-
tients and allowed us to prolong the incubation period (up to
72 h). In a previously used model of an electrically paced
isolated mouse left atrium [6] the acute doxorubicin toxicity (1 h
incubation) was measured using a higher dose of doxorubicin
(35 μM), which corresponded with heart concentrations in mice
[36]. The concentration of the flavonoids was based on initial
cytotoxicity screening where most compounds showed accep-
table cytotoxicity by 100 μM. Both models gave similar results
and demonstrated that the compounds F4 (monoHER) and F7
are the best protectors of the series. For F5 and F10, aTable 4
Correlation between the percentual protection of cardiomyocytes against doxorubici
Protection % CR inhibition LPO inhibition Fe3+
chelatio
IC50 (μM) IC50 (μM)
24 h
R −0.047 −0.159 0.479
p 0.897 0.683 0.161
48 h
R 0.445 0.228 0.139
p 0.198 0.554 0.702
72 h
R 0.651 0.476 −0.249
p 0.042∗ 0.195 0.488
R — Pearson's product moment correlation coefficient, p — observed significance
∗Significant relationship between the two variables (pb0.05).remarkable decrease in protection against the doxorubicin-
induced cardiomyocyte toxicity was found during incubation
(24 vs. 48 and 72 h). This might be due to their own toxicity. It
is known that the metabolite of quercetin (F5), quercetin–
quinone methide, is thiol-reactive and rapidly forms adducts
with glutathione. This reaction may lead to toxic effects such as
increased membrane permeability or altered function of the SH-
containing enzymes [37]. The structures of F10 and F1 resemble
that of quercetin the most and indeed, their biochemical behav-
iour is similar in many aspects.
Low intrinsic toxicity of the compounds is of course an im-
portant requirement to allow eventual clinical application. We
have tested the cytotoxicity of the flavonoids in the H9c2 cells.
With exception of F1, F5 and F10, all the compounds had
acceptable toxicity. F7 was the least toxic compound of the
series. Apparently high cytotoxicity has consequences in car-
dioprotection: the beneficial effects of the compounds (if any)
do not last for long as they are overwhelmed by another type of
toxicity. In this way our study points out the limitations of short-
term (acute) models of doxorubicin cardiotoxicity. For example,
quercetin was previously designated as an excellent cardiopro-
tector against anthracycline-induced toxicity in neonatal
cardiomyocytes [7], however, its effects were only followed
for 8 h, which may lead to an overestimation of the beneficial
effects of these types of compounds (i.e. compounds with
reactive intermediates). We have found that the protection by
quercetin was still high at 24 h but it decreased during the next
48 h, whereas the effect of F4 (monoHER) or F7 lasted during
the whole experiment. Cytotoxicity of the flavonoids was found
to be negatively correlated with the percentage of cardioprotec-
tion at 72 h (pb0.018) (Table 4).
Interactions of the anthracyclines with iron are well des-
cribed and include not only iron-catalyzed formation of free
radicals but also severe perturbations of iron homeostasis in-
duced by the anthracyclines [38,39,40]. All the tested flavo-
noids were able to chelate iron and it was found that the number
of chelating sites present in the molecule determines the degree
of iron chelation. However, no link was found between the
cardioprotective effects of the flavonoids and their iron-che-
lating ability. The discrepancy between the effect of monoHER
(F4) in the calcein assay (low) and site-specific scavengingn-induced LDH leakage and various biochemical parameters of the flavonoid
n %
HOU scavenging ks [M−1 s−1]×109 Cytotoxicity
Without EDTA With EDTA IC50 (μM)
−0.274 −0.459 −0.093
0.444 0.182 0.799
0.265 −0.320 0.676
0.459 0.368 0.063
0.570 −0.102 0.722
0.085 0.778 0.018∗
of the test.
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Fe2+ and Fe3+. Although iron is introduced in its ferrous form in
the calcein assay, it is rapidly oxidized to its ferric form under
the conditions of the experiment. It is not possible to keep it in
the ferrous form using reducing agents (e.g. ascorbate) because
this leads to a degradation of the probe [41]. Therefore, the
calcein assay gives information about the Fe3+-chelating ability
whereas in the 2-deoxyribose assay, iron is present in its Fe2+
form due to the presence of ascorbate. It has been suggested that
the flavonoids chelate iron as Fe2+ and their ability to chelate
Fe3+ is related to their capacity to reduce Fe3+ to Fe2+ before
association [42], which is apparently larger in F5 and F6 than in
F4. Although we were able to identify minor nuances in the
iron-chelating behaviour of various flavonoids, their inability to
displace iron bound to doxorubicin indicates their overall weak
chelating capacity when compared with strong non-flavonoid
chelators like SIH or EDTA. On the other hand, our results
suggest that displacing iron from its complexes with doxo-
rubicin is not critical for the cardioprotective action of a
compound.
The deoxyribose assay for hydroxyl radical scavenging, that
has been employed to investigate iron chelation, also gives
information about antioxidant behaviour of the compounds. In
the presence of EDTA, information on the direct antioxidant
behaviour of the flavonoids (i.e. without the participation of
iron chelation) is provided. An increase of scavenging activity
in the absence of EDTA is indicative for iron chelation by the
flavonoids and the influence of iron chelation on total anti-
oxidant capacity by the flavonoids. Interestingly, we have found
that under the conditions of the assay, the compound F5 (quer-
cetin) did not scavenge hydroxyl radicals in presence of EDTA
(which does not allow site-specific scavenging). On the con-
trary, it acted as mild pro-oxidant. On the other hand, quercetin
acted as a powerful protector against lipid peroxidation (LPO).
This discrepancy is not very surprising, the fine balance
between the anti- and pro-oxidant properties of the flavonoids is
well known and it obviously depends on the exact conditions of
the assays. Similar results were previously achieved by Laugh-
ton et al. [43]. As can be seen from the ks values and the IC50
values for LPO, all the compounds possess good antioxidant
properties. Indeed, it was previously found that the catechol
moiety in combination with C2–C3 double bond and 4-oxo
function are the essential structural elements for potent anti-
oxidant activity and that 3-substituted compounds are superior
to the 7-substituted compounds in LPO assay [19]. Based on our
findings, we conclude that neither hydroxyl radical scavenging
nor inhibition of lipid peroxidation seem to predict the cardio-
protective potential of the flavonoids.
The inhibition of doxorubicin carbonyl reduction was as-
sessed in order to evaluate the involvement of cardiotoxic me-
tabolite formation in prevention of the doxorubicin-induced
cardiotoxicity. There is one additional reason for blocking
doxorubicin reduction to doxorubicinol. It has been shown that
an increased carbonyl reduction, which is inducible by anthra-
cyclines, might also lead to the development of resistance to
chemotherapy [44]. To date, very few studies have been con-
ducted on the inhibitory effects of flavonoids on carbonylreductases [45,46], although it is known for a long time that the
flavonoids quercetin, quercitrin or rutin are excellent CR in-
hibitors. To our knowledge, this study is the first to combine the
biochemical inhibition of doxorubicinol formation with cardio-
protection evaluation. Based on the IC50 values we have
identified the compounds F5, F6 and F10 as the best inhibitors
of carbonyl reductases of the series. On the contrary, F7 was the
worst inhibitor. The quaternary ammonium moiety is not only
bulky but it is also positively charged and thus it can affect the
appropriate electrostatic interaction between enzyme and in-
hibitor. From the three flavonoids with a quaternary ammonium
group, F9 was the best inhibitor (preserved 7-OH, substituted 3-
OH) and F7 was the worst (substituted 7-OH). This means that
an absence (F1, F2, F3, F8) or even a substitution (F4, F7) of
C7–OH clearly decrease the degree of inhibition. The fact that
F7 was a weak inhibitor further confirms the role of C7–OH in
the enzyme–inhibitor interaction and the negative influence of
the quaternary ammonium moiety on the inhibitory properties
of the flavonoids. If we take into account that F7 and F4
(monoHER) are among the best cardioprotectors of the present
study, the importance of carbonyl reductase inhibition seems
unlikely. This assumption is further supported by the Pearson
product moment correlation analysis, which revealed weak
correlation (pb0.042) between carbonyl reductase IC50 and
cardiomyocyte protection at 72 h (Table 4).
In summary, it can be stated that the efficient cardioprotec-
tive compounds are not cytotoxic by themselves. High efficacy
in carbonyl reductase inhibition is not critical for the cardio-
protective action of the flavonoids. Moreover, no correlation
was found between the inhibition of LPO or hydroxyl radical
scavenging and the cardioprotective effects. It was found that
iron chelation increased the scavenging capacity of the flavo-
noids (through site-specific scavenging). The present study
shows that besides monoHER also compound F7 has excellent
cardioprotective properties. Cardioprotection is however not
clearly associated with a single physico-chemical or biochem-
ical property of the flavonoid.
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